# Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up

> **NCT00001476** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 14 (actual)

## Conditions studied

- Chronic Granulomatous Disease
- Communicable Disease

## Interventions

- **DRUG:** Gene Therapy Method for CGD
- **DEVICE:** Isolex 300i Magnetic Cell Selector

## Key facts

- **NCT ID:** NCT00001476
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-06-01
- **Primary completion:** 2010-12-13
- **Final completion:** 2010-12-13
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001476, "Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00001476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*